Skip to main content
Erschienen in: Cancer and Metastasis Reviews 4/2015

01.12.2015 | NON-THEMATIC REVIEW

The origin of prostate metastases: emerging insights

verfasst von: Matteo Santoni, Francesco Piva, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Roberto Iacovelli, Rossana Berardi, Daniele Santini, Rodolfo Montironi

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The outcome of patients with prostate cancer (PCa) is mainly dependent on the presence or absence of distant metastases. Although several advances have been made in understanding the biological basis of this tumor, the mechanisms underlying PCa metastatic spread are not fully clear. The lack of a clear origin for PCa metastasis may be partially due to the evidence of PCa heterogeneity between primary tumor and metastases and among different metastatic sites. Cross-metastatic seeding and the de novo monoclonal seeding of daughter metastases have been proposed as crucial events during metastasis. This process requires the contribution of tumor environment, which modulates cancer cell homing and growth, and involves several components including cancer stem cells (CSCs), tumor secreted microvesicles, circulating tumor cells (CTCs), and immune cells. In this review, we have focused on the recent findings on the origin of prostate metastasis, showing the contribution of tumor microenvironment to this evolutionary process.
Literatur
1.
Zurück zum Zitat Aus, G., Robinson, D., Rosell, J., Sandblom, G., & Varenhorst, E. (2005). Survival in prostate carcinoma—outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up. Cancer, 103(5), 943–951.PubMedCrossRef Aus, G., Robinson, D., Rosell, J., Sandblom, G., & Varenhorst, E. (2005). Survival in prostate carcinoma—outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up. Cancer, 103(5), 943–951.PubMedCrossRef
2.
Zurück zum Zitat Wyatt, A. W., Mo, F., Wang, Y., & Collins, C. C. (2013). The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology, 15(3), 301–308.PubMedCentralPubMedCrossRef Wyatt, A. W., Mo, F., Wang, Y., & Collins, C. C. (2013). The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology, 15(3), 301–308.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., et al. (2011). The genomic complexity of primary human prostate cancer. Nature, 470(7333), 214–220.PubMedCentralPubMedCrossRef Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., et al. (2011). The genomic complexity of primary human prostate cancer. Nature, 470(7333), 214–220.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., et al. (2013). Punctuated evolution of prostate cancer genomes. Cell, 153(3), 666–677.PubMedCentralPubMedCrossRef Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., et al. (2013). Punctuated evolution of prostate cancer genomes. Cell, 153(3), 666–677.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., & Helgeson, B. E. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10(2), 177–188.PubMedCentralPubMedCrossRef Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., & Helgeson, B. E. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10(2), 177–188.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Wang, L., Williamson, S. R., Zhang, S., Huang, J., Montironi, R., & Davison, D. D. (2014). Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis. doi:10.1002/mc.22162. Wang, L., Williamson, S. R., Zhang, S., Huang, J., Montironi, R., & Davison, D. D. (2014). Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis. doi:10.​1002/​mc.​22162.
7.
Zurück zum Zitat Attard, G., Jameson, C., Moreira, J., Flohr, P., Parker, C., & Dearnaley, D. (2009). Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. Journal of Clinical Pathology, 62(4), 373–376.PubMedCrossRef Attard, G., Jameson, C., Moreira, J., Flohr, P., Parker, C., & Dearnaley, D. (2009). Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. Journal of Clinical Pathology, 62(4), 373–376.PubMedCrossRef
8.
Zurück zum Zitat Lindberg, J., Kristiansen, A., Wiklund, P., Grönberg, H., & Egevad, L. (2015). Tracking the origin of metastatic prostate cancer. European Urology, 67(5), 819–822.PubMedCrossRef Lindberg, J., Kristiansen, A., Wiklund, P., Grönberg, H., & Egevad, L. (2015). Tracking the origin of metastatic prostate cancer. European Urology, 67(5), 819–822.PubMedCrossRef
9.
Zurück zum Zitat Trudel, D., Downes, M. R., Sykes, J., Kron, K. J., Trachtenberg, J., & van der Kwast, T. H. (2014). Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. European Journal of Cancer, 50(9), 1610–1616.PubMedCrossRef Trudel, D., Downes, M. R., Sykes, J., Kron, K. J., Trachtenberg, J., & van der Kwast, T. H. (2014). Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. European Journal of Cancer, 50(9), 1610–1616.PubMedCrossRef
10.
Zurück zum Zitat Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M., Papaemmanuil, E., et al. (2015). The evolutionary history of lethal metastatic prostate cancer. Nature, 520(7547), 353–357.PubMedCentralPubMedCrossRef Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M., Papaemmanuil, E., et al. (2015). The evolutionary history of lethal metastatic prostate cancer. Nature, 520(7547), 353–357.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Hong, M. K., Macintyre, G., Wedge, D. C., Van Loo, P., Patel, K., & Lunke, S. (2015). Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 6, 6605.PubMedCentralPubMedCrossRef Hong, M. K., Macintyre, G., Wedge, D. C., Van Loo, P., Patel, K., & Lunke, S. (2015). Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 6, 6605.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Piva, F., Santoni, M., Scarpelli, M., Briganti, A., Montorsi, F., & Montironi, R. (2015). Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the origin of metastatic prostate cancer. European Urology. doi:10.1016/j.eururo.2015.07.011. Piva, F., Santoni, M., Scarpelli, M., Briganti, A., Montorsi, F., & Montironi, R. (2015). Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the origin of metastatic prostate cancer. European Urology. doi:10.​1016/​j.​eururo.​2015.​07.​011.
13.
Zurück zum Zitat Geem, Z. W., Kim, J. H., & Loganathan, G. V. (2001). A new heuristic optimization algorithm: harmony search. SIMULATION, 76(2), 60–68.CrossRef Geem, Z. W., Kim, J. H., & Loganathan, G. V. (2001). A new heuristic optimization algorithm: harmony search. SIMULATION, 76(2), 60–68.CrossRef
14.
Zurück zum Zitat Chen, X. S., Ong, Y. S., & Lim, M. H. (2010). Research frontier: memetic computation—past, present & future. IEEE Computational Intelligence Magazine, 5(2), 24–36.CrossRef Chen, X. S., Ong, Y. S., & Lim, M. H. (2010). Research frontier: memetic computation—past, present & future. IEEE Computational Intelligence Magazine, 5(2), 24–36.CrossRef
15.
Zurück zum Zitat Casás-Selves, M., & Degregori, J. (2011). How cancer shapes evolution, and how evolution shapes cancer. Evolution (NY), 4(4), 624–634. Casás-Selves, M., & Degregori, J. (2011). How cancer shapes evolution, and how evolution shapes cancer. Evolution (NY), 4(4), 624–634.
16.
Zurück zum Zitat Jordan, C. T., Guzman, M. L., & Noble, M. (2006). Cancer stem cells. The New England Journal of Medicine, 355(12), 1253–1261.PubMedCrossRef Jordan, C. T., Guzman, M. L., & Noble, M. (2006). Cancer stem cells. The New England Journal of Medicine, 355(12), 1253–1261.PubMedCrossRef
17.
Zurück zum Zitat Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews Cancer, 5(4), 275–284.PubMedCrossRef Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews Cancer, 5(4), 275–284.PubMedCrossRef
18.
Zurück zum Zitat Rybak, A. P., Bristow, R. G., & Kapoor, A. (2015). Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget, 6(4), 1900–1919.PubMedCentralPubMedCrossRef Rybak, A. P., Bristow, R. G., & Kapoor, A. (2015). Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget, 6(4), 1900–1919.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323.PubMedCrossRef Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323.PubMedCrossRef
20.
Zurück zum Zitat Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.PubMedCrossRef Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.PubMedCrossRef
21.
Zurück zum Zitat van der Pluijm, G. (2011). Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 48(1), 37–43.PubMedCrossRef van der Pluijm, G. (2011). Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 48(1), 37–43.PubMedCrossRef
22.
Zurück zum Zitat Wen, S., Niu, Y., Yeh, S., & Chang, C. (2015). BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. International Journal of Oncolology. doi:10.3892/ijo.2015.3060. Wen, S., Niu, Y., Yeh, S., & Chang, C. (2015). BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. International Journal of Oncolology. doi:10.​3892/​ijo.​2015.​3060.
23.
Zurück zum Zitat Tang, K.D., Holzapfel, B.M., Liu, J., Lee, T.K., Ma, S., Jovanovic, L. (2015). Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget, in press. Tang, K.D., Holzapfel, B.M., Liu, J., Lee, T.K., Ma, S., Jovanovic, L. (2015). Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget, in press.
24.
Zurück zum Zitat Marian, L., Katarina, K., & Vladimir, B. (2013). Essentials of circulating tumor cells for clinical research and practice. Critival Reviews in Oncology/Hematology, 88(2), 338–356.CrossRef Marian, L., Katarina, K., & Vladimir, B. (2013). Essentials of circulating tumor cells for clinical research and practice. Critival Reviews in Oncology/Hematology, 88(2), 338–356.CrossRef
25.
Zurück zum Zitat Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., & Tanaka, E. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13(23), 7053–7058.PubMedCrossRef Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., & Tanaka, E. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13(23), 7053–7058.PubMedCrossRef
26.
Zurück zum Zitat Okegawa, T., Nutahara, K., & Higashihara, E. (2009). Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. The Journal of Urology, 181(3), 1091–1097.PubMedCrossRef Okegawa, T., Nutahara, K., & Higashihara, E. (2009). Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. The Journal of Urology, 181(3), 1091–1097.PubMedCrossRef
27.
Zurück zum Zitat Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65(4), 713–718.PubMedCrossRef Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65(4), 713–718.PubMedCrossRef
28.
Zurück zum Zitat Scher, H. I., Jia, X., de Bono, J. S., Fleisher, M., Pienta, K. J., Raghavan, D., et al. (2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. The Lancet Oncology, 10(3), 233–239.PubMedCentralPubMedCrossRef Scher, H. I., Jia, X., de Bono, J. S., Fleisher, M., Pienta, K. J., Raghavan, D., et al. (2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. The Lancet Oncology, 10(3), 233–239.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Abe, Y., Matsumoto, S., Kito, K., & Ueda, N. (2000). Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. The Journal of Biological Chemistry, 275(28), 21525–21531.PubMedCrossRef Abe, Y., Matsumoto, S., Kito, K., & Ueda, N. (2000). Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. The Journal of Biological Chemistry, 275(28), 21525–21531.PubMedCrossRef
30.
Zurück zum Zitat Sun, H., Zhang, L., Shi, C., Hu, P., Yan, W., & Wang, Z. (2015). TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. Oncotarget, 6(14), 12392–12404.PubMedCentralPubMedCrossRef Sun, H., Zhang, L., Shi, C., Hu, P., Yan, W., & Wang, Z. (2015). TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. Oncotarget, 6(14), 12392–12404.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Luga, V., Zhang, L., Viloria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., & Chiu, E. (2012). Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell, 151(7), 1542–1556.PubMedCrossRef Luga, V., Zhang, L., Viloria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., & Chiu, E. (2012). Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell, 151(7), 1542–1556.PubMedCrossRef
32.
Zurück zum Zitat Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., & Moreno-Bueno, G. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891.PubMedCentralPubMedCrossRef Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., & Moreno-Bueno, G. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Chowdhury, R., Webber, J. P., Gurney, M., Mason, M. D., Tabi, Z., & Clayton, A. (2015). Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget, 6(2), 715–731.PubMedCentralPubMedCrossRef Chowdhury, R., Webber, J. P., Gurney, M., Mason, M. D., Tabi, Z., & Clayton, A. (2015). Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget, 6(2), 715–731.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Lundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., et al. (2014). Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One, 9(9), e108925.PubMedCentralPubMedCrossRef Lundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., et al. (2014). Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One, 9(9), e108925.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Kawakami, K., Fujita, Y., Kato, T., Mizutani, K., Kameyama, K., Tsumoto, H., et al. (2015). Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. International Journal of Oncology, 47(1), 384–390.PubMed Kawakami, K., Fujita, Y., Kato, T., Mizutani, K., Kameyama, K., Tsumoto, H., et al. (2015). Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. International Journal of Oncology, 47(1), 384–390.PubMed
36.
Zurück zum Zitat Trerotola, M., Ganguly, K. K., Fazli, L., Fedele, C., Lu, H., Dutta, A., et al. (2015). Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget, 6(16), 14318–14328.PubMedCentralPubMedCrossRef Trerotola, M., Ganguly, K. K., Fazli, L., Fedele, C., Lu, H., Dutta, A., et al. (2015). Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget, 6(16), 14318–14328.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Sandvig, K., & Llorente, A. (2012). Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Molelucar & Cellular Proteomics, 11(7), M111.012914.CrossRef Sandvig, K., & Llorente, A. (2012). Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Molelucar & Cellular Proteomics, 11(7), M111.012914.CrossRef
38.
Zurück zum Zitat Deryugina, E. I., Conn, E. M., Wortmann, A., Partridge, J. J., Kupriyanova, T. A., Ardi, V. C., et al. (2009). Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Molecular Cancer Research, 7(8), 1197–1211.PubMedCentralPubMedCrossRef Deryugina, E. I., Conn, E. M., Wortmann, A., Partridge, J. J., Kupriyanova, T. A., Ardi, V. C., et al. (2009). Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Molecular Cancer Research, 7(8), 1197–1211.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Zöller, M. (2009). Tetraspanins: push and pull in suppressing and promoting metastasis. Nature Reviews Cancer, 9(1), 40–55.PubMedCrossRef Zöller, M. (2009). Tetraspanins: push and pull in suppressing and promoting metastasis. Nature Reviews Cancer, 9(1), 40–55.PubMedCrossRef
40.
Zurück zum Zitat Tang, Y., Kesavan, P., Nakada, M. T., & Yan, L. (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Molecular Cancer Research, 2(2), 73–80.PubMed Tang, Y., Kesavan, P., Nakada, M. T., & Yan, L. (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Molecular Cancer Research, 2(2), 73–80.PubMed
41.
Zurück zum Zitat Zhong, W. D., Liang, Y. X., Lin, S. X., Li, L., He, H. C., Bi, X. C., et al. (2012). Expression of CD147 is associated with prostate cancer progression. International Journal of Cancer, 130(2), 300–308.CrossRef Zhong, W. D., Liang, Y. X., Lin, S. X., Li, L., He, H. C., Bi, X. C., et al. (2012). Expression of CD147 is associated with prostate cancer progression. International Journal of Cancer, 130(2), 300–308.CrossRef
42.
Zurück zum Zitat Gnanasekar, M., Thirugnanam, S., Zheng, G., Chen, A., & Ramaswamy, K. (2009). Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. International Journal of Oncology, 34(5), 1241–1246.PubMed Gnanasekar, M., Thirugnanam, S., Zheng, G., Chen, A., & Ramaswamy, K. (2009). Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. International Journal of Oncology, 34(5), 1241–1246.PubMed
43.
Zurück zum Zitat Miao, H. Q., Lee, P., Lin, H., Soker, S., & Klagsbrun, M. (2000). Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. The FASEB Journal, 14(15), 2532–2539.PubMedCrossRef Miao, H. Q., Lee, P., Lin, H., Soker, S., & Klagsbrun, M. (2000). Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. The FASEB Journal, 14(15), 2532–2539.PubMedCrossRef
44.
Zurück zum Zitat Jia, H., Cheng, L., Tickner, M., Bagherzadeh, A., Selwood, D., & Zachary, I. (2010). Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. British Journal of Cancer, 102(3), 541–552.PubMedCentralPubMedCrossRef Jia, H., Cheng, L., Tickner, M., Bagherzadeh, A., Selwood, D., & Zachary, I. (2010). Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. British Journal of Cancer, 102(3), 541–552.PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Øverbye, A., Skotland, T., Koehler, C.J., Thiede, B., Seierstad, T., Berge, V. (2015). Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget, in press. Øverbye, A., Skotland, T., Koehler, C.J., Thiede, B., Seierstad, T., Berge, V. (2015). Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget, in press.
46.
Zurück zum Zitat Bar-Peled, L., Schweitzer, L.D., Zoncu, R., Sabatini, D.M. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell, 150(6), 1196–1208. Bar-Peled, L., Schweitzer, L.D., Zoncu, R., Sabatini, D.M. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell, 150(6), 1196–1208.
47.
Zurück zum Zitat Gu, T. L., Cherry, J., Tucker, M., Wu, J., Reeves, C., & Polakiewicz, R. D. (2010). Identification of activated Tnk1 kinase in Hodgkin’s lymphoma. Leukemia, 24(4), 861–865.PubMedCrossRef Gu, T. L., Cherry, J., Tucker, M., Wu, J., Reeves, C., & Polakiewicz, R. D. (2010). Identification of activated Tnk1 kinase in Hodgkin’s lymphoma. Leukemia, 24(4), 861–865.PubMedCrossRef
48.
Zurück zum Zitat Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orlowski, A., et al. (2013). Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochima et Biophysica Acta, 1831(7), 1302–1309.CrossRef Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orlowski, A., et al. (2013). Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochima et Biophysica Acta, 1831(7), 1302–1309.CrossRef
49.
Zurück zum Zitat Hessvik, N. P., Phuyal, S., Brech, A., Sandvig, K., & Llorente, A. (2012). Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochimica et Biophysica Acta, 1819, 1154–1163.PubMedCrossRef Hessvik, N. P., Phuyal, S., Brech, A., Sandvig, K., & Llorente, A. (2012). Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochimica et Biophysica Acta, 1819, 1154–1163.PubMedCrossRef
50.
Zurück zum Zitat Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V., & Languino, L. R. (2015). The αvβ6 integrin is transferred intercellularly via exosomes. The Journal of Biological Chemistry, 290(8), 4545–4551.PubMedCrossRef Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V., & Languino, L. R. (2015). The αvβ6 integrin is transferred intercellularly via exosomes. The Journal of Biological Chemistry, 290(8), 4545–4551.PubMedCrossRef
51.
Zurück zum Zitat De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., et al. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7(4), 256–269.PubMedCentralPubMedCrossRef De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., et al. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7(4), 256–269.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Vignozzi, L., & Maggi, M. (2004). Prostate cancer: intriguing data on inflammation and prostate cancer. Nature Reviews. Urology, 11(7), 369–370.CrossRef Vignozzi, L., & Maggi, M. (2004). Prostate cancer: intriguing data on inflammation and prostate cancer. Nature Reviews. Urology, 11(7), 369–370.CrossRef
53.
Zurück zum Zitat Sfanos, K. S., Hempe, H. A., & De Marzo, A. M. (2014). The role of inflammation in prostate cancer. Advances in Experimental Medicine and Biology, 816, 153–181.PubMedCrossRef Sfanos, K. S., Hempe, H. A., & De Marzo, A. M. (2014). The role of inflammation in prostate cancer. Advances in Experimental Medicine and Biology, 816, 153–181.PubMedCrossRef
54.
Zurück zum Zitat Wang, W., Bergh, A., & Damber, J. E. (2009). Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate, 69(13), 1378–1386.PubMedCrossRef Wang, W., Bergh, A., & Damber, J. E. (2009). Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate, 69(13), 1378–1386.PubMedCrossRef
55.
Zurück zum Zitat Nguyen, D. P., Li, J., Yadav, S. S., & Tewari, A. K. (2014). Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU International, 114(2), 168–176.PubMedCrossRef Nguyen, D. P., Li, J., Yadav, S. S., & Tewari, A. K. (2014). Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU International, 114(2), 168–176.PubMedCrossRef
56.
Zurück zum Zitat Vidal, A. C., Howard, L. E., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., & Freedland, S. J. (2015). Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clinical Cancer Research, 21(4), 756–762.PubMedCrossRef Vidal, A. C., Howard, L. E., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., & Freedland, S. J. (2015). Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clinical Cancer Research, 21(4), 756–762.PubMedCrossRef
57.
Zurück zum Zitat Zarif, J. C., Taichman, R. S., & Pienta, K. J. (2014). TAM macrophages promote growth and metastasis within the cancer ecosystem. Oncoimmunology, 3;3(7), e941734.CrossRef Zarif, J. C., Taichman, R. S., & Pienta, K. J. (2014). TAM macrophages promote growth and metastasis within the cancer ecosystem. Oncoimmunology, 3;3(7), e941734.CrossRef
58.
Zurück zum Zitat Soki, F. N., Koh, A. J., Jones, J. D., Kim, Y. W., Dai, J., Keller, E. T., Pienta, K. J., et al. (2014). Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. The Journal of Biological Chemistry, 289, 24560–24572.PubMedCentralPubMedCrossRef Soki, F. N., Koh, A. J., Jones, J. D., Kim, Y. W., Dai, J., Keller, E. T., Pienta, K. J., et al. (2014). Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. The Journal of Biological Chemistry, 289, 24560–24572.PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Ding, X., Yang, D. R., Xia, L., Chen, B., Yu, S., Niu, Y., et al. (2015). Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. Molecular Cancer, 14, 16.PubMedCentralPubMedCrossRef Ding, X., Yang, D. R., Xia, L., Chen, B., Yu, S., Niu, Y., et al. (2015). Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. Molecular Cancer, 14, 16.PubMedCentralPubMedCrossRef
60.
Zurück zum Zitat Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009). CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. The Journal of Biological Chemistry, 284(49), 34342–34354.PubMedCentralPubMedCrossRef Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009). CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. The Journal of Biological Chemistry, 284(49), 34342–34354.PubMedCentralPubMedCrossRef
61.
62.
Zurück zum Zitat Luo, Y., Jiang, Q.W., Wu, J.Y., Qiu, J.G., Zhang, W.J., Mei, X.L., et al. (2015). Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer. Oncotarget, in press. Luo, Y., Jiang, Q.W., Wu, J.Y., Qiu, J.G., Zhang, W.J., Mei, X.L., et al. (2015). Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer. Oncotarget, in press.
63.
Zurück zum Zitat Santoni, M., Bracarda, S., Nabissi, M., Massari, F., Conti, A., Bria, E., et al. (2014). CXC and CC chemokines as angiogenic modulators in non-haematological tumors. Biomed Research International, 768758. Santoni, M., Bracarda, S., Nabissi, M., Massari, F., Conti, A., Bria, E., et al. (2014). CXC and CC chemokines as angiogenic modulators in non-haematological tumors. Biomed Research International, 768758.
64.
Zurück zum Zitat Izumi, K., Fang, L. Y., Mizokami, A., Namiki, M., Li, L., Lin, W. J., et al. (2013). Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Molecular Medicine, 5(9), 1383–1401.PubMedCentralPubMedCrossRef Izumi, K., Fang, L. Y., Mizokami, A., Namiki, M., Li, L., Lin, W. J., et al. (2013). Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Molecular Medicine, 5(9), 1383–1401.PubMedCentralPubMedCrossRef
65.
Zurück zum Zitat Santoni, M., Conti, A., Piva, F., Massari, F., Ciccarese, C., Burattini, L., et al. (2015). Role of STAT3 pathway in genitourinary tumors. Future Science, in press. Santoni, M., Conti, A., Piva, F., Massari, F., Ciccarese, C., Burattini, L., et al. (2015). Role of STAT3 pathway in genitourinary tumors. Future Science, in press.
66.
Zurück zum Zitat Zhang, K., Zhao, H., Ji, Z., Zhang, C., Zhou, P., Wang, L., et al. (2015). Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition. Oncogene. doi:10.1038/onc.2015.184. Zhang, K., Zhao, H., Ji, Z., Zhang, C., Zhou, P., Wang, L., et al. (2015). Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition. Oncogene. doi:10.​1038/​onc.​2015.​184.
67.
Zurück zum Zitat Kolijn, K., Verhoef, E.I., van Leenders, G.J. (2015) Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget, in press. Kolijn, K., Verhoef, E.I., van Leenders, G.J. (2015) Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget, in press.
68.
Zurück zum Zitat Lin, T. H., Izumi, K., Lee, S. O., Lin, W. J., Yeh, S., & Chang, C. (2013). Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death & Disease. doi:10.1038/cddis.2013.270. Lin, T. H., Izumi, K., Lee, S. O., Lin, W. J., Yeh, S., & Chang, C. (2013). Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death & Disease. doi:10.​1038/​cddis.​2013.​270.
69.
Zurück zum Zitat Chen, Y., Tian, Y., Ji, Z., Liu, Z., & Shang, D. (2015). CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer. Tumour Biology, 36(7), 5537–5541.PubMedCrossRef Chen, Y., Tian, Y., Ji, Z., Liu, Z., & Shang, D. (2015). CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer. Tumour Biology, 36(7), 5537–5541.PubMedCrossRef
70.
Zurück zum Zitat Zalucha, J. L., Jung, Y., Joseph, J., Wang, J., Berry, J. E., Shiozawa, Y., et al. (2015). The role of osteoclasts in early dissemination of prostate cancer tumor cells. Journal of Cancer Stem Cell Research, 3, e1005.PubMedCentralPubMedCrossRef Zalucha, J. L., Jung, Y., Joseph, J., Wang, J., Berry, J. E., Shiozawa, Y., et al. (2015). The role of osteoclasts in early dissemination of prostate cancer tumor cells. Journal of Cancer Stem Cell Research, 3, e1005.PubMedCentralPubMedCrossRef
71.
Zurück zum Zitat Arnold, R. S., Fedewa, S. A., Goodman, M., Osunkoya, A. O., Kissick, H. T., Morrissey, C., et al. (2015). Bone metastasis in prostate cancer: recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Bone, 78, 81–86.PubMedCrossRef Arnold, R. S., Fedewa, S. A., Goodman, M., Osunkoya, A. O., Kissick, H. T., Morrissey, C., et al. (2015). Bone metastasis in prostate cancer: recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Bone, 78, 81–86.PubMedCrossRef
72.
Zurück zum Zitat Vicente-Dueñas, C., Gutiérrez de Diego, J., Rodríguez, F. D., Jiménez, R., & Cobaleda, C. (2009). The role of cellular plasticity in cancer development. Current Medicinal Chemistry, 16(28), 3676–3685.PubMedCrossRef Vicente-Dueñas, C., Gutiérrez de Diego, J., Rodríguez, F. D., Jiménez, R., & Cobaleda, C. (2009). The role of cellular plasticity in cancer development. Current Medicinal Chemistry, 16(28), 3676–3685.PubMedCrossRef
73.
Zurück zum Zitat Bishop, J. L., Davies, A., Ketola, K., & Zoubeidi, A. (2015). Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocrine Related Cancer, 22(3), R165–182.PubMedCrossRef Bishop, J. L., Davies, A., Ketola, K., & Zoubeidi, A. (2015). Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocrine Related Cancer, 22(3), R165–182.PubMedCrossRef
74.
Zurück zum Zitat Santoni, M., Conti, A., Burattini, L., Berardi, R., Scarpelli, M., Cheng, L., et al. (2014). Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochimica et Biophysica Acta-Reviews of Cancer, 1846(2), 630–637.CrossRef Santoni, M., Conti, A., Burattini, L., Berardi, R., Scarpelli, M., Cheng, L., et al. (2014). Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochimica et Biophysica Acta-Reviews of Cancer, 1846(2), 630–637.CrossRef
75.
Zurück zum Zitat Jadaan, D.Y., Jadaan, M.M., McCabe, J.P. (2015). Cellular plasticity in prostate cancer bone metastasis. Prostate Cancer, 651580, doi: 10.1155/2015/651580. Jadaan, D.Y., Jadaan, M.M., McCabe, J.P. (2015). Cellular plasticity in prostate cancer bone metastasis. Prostate Cancer, 651580, doi: 10.​1155/​2015/​651580.
76.
Zurück zum Zitat Xu, J., Wang, R., Xie, Z. H., Odero-Marah, V., Pathak, S., Multani, A., et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate, 66(15), 1664–1673.PubMedCrossRef Xu, J., Wang, R., Xie, Z. H., Odero-Marah, V., Pathak, S., Multani, A., et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate, 66(15), 1664–1673.PubMedCrossRef
77.
Zurück zum Zitat Josson, S., Sharp, S., Sung, S. Y., Johnstone, P. A., Aneja, R., Wang, R., et al. (2010). Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. Journal of Oncology. doi:10.1155/2010/232831.PubMedCentralPubMed Josson, S., Sharp, S., Sung, S. Y., Johnstone, P. A., Aneja, R., Wang, R., et al. (2010). Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. Journal of Oncology. doi:10.​1155/​2010/​232831.PubMedCentralPubMed
78.
Zurück zum Zitat D'Amico, L., Patanè, S., Grange, C., Bussolati, B., Isella, C., Fontani, L., et al. (2013). Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. British Journal of Cancer, 108(12), 2525–2536.PubMedCentralPubMedCrossRef D'Amico, L., Patanè, S., Grange, C., Bussolati, B., Isella, C., Fontani, L., et al. (2013). Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. British Journal of Cancer, 108(12), 2525–2536.PubMedCentralPubMedCrossRef
79.
Zurück zum Zitat Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298–1312.PubMedCentralPubMedCrossRef Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298–1312.PubMedCentralPubMedCrossRef
80.
Zurück zum Zitat Eaton, C. L., Colombel, M., van der Pluijm, G., Cecchini, M., Wetterwald, A., Lippitt, J., et al. (2010). Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate, 70(8), 875–882.PubMed Eaton, C. L., Colombel, M., van der Pluijm, G., Cecchini, M., Wetterwald, A., Lippitt, J., et al. (2010). Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate, 70(8), 875–882.PubMed
81.
Zurück zum Zitat Fournier, P. G., Juárez, P., Jiang, G., Clines, G. A., Niewolna, M., Kim, H. S., et al. (2015). The TGF-β signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell, 27(6), 809–821.PubMedCrossRef Fournier, P. G., Juárez, P., Jiang, G., Clines, G. A., Niewolna, M., Kim, H. S., et al. (2015). The TGF-β signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell, 27(6), 809–821.PubMedCrossRef
82.
Zurück zum Zitat Bonci, D., Coppola, V., Patrizii, M., Addario, A., Cannistraci, A., Francescangeli, F., et al. (2015). A microRNA code for prostate cancer metastasis. Oncogene. doi:10.1038/onc.2015.176.PubMed Bonci, D., Coppola, V., Patrizii, M., Addario, A., Cannistraci, A., Francescangeli, F., et al. (2015). A microRNA code for prostate cancer metastasis. Oncogene. doi:10.​1038/​onc.​2015.​176.PubMed
83.
Zurück zum Zitat Chang, Y. S., Chen, W. Y., Yin, J. J., Sheppard-Tillman, H., Huang, J., & Liu, Y. N. (2015). EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Research, 75(15), 3077–3086.PubMedCrossRef Chang, Y. S., Chen, W. Y., Yin, J. J., Sheppard-Tillman, H., Huang, J., & Liu, Y. N. (2015). EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Research, 75(15), 3077–3086.PubMedCrossRef
84.
Zurück zum Zitat Li, X., Liu, Y., Wu, B., Dong, Z., Wang, Y., Lu, J., et al. (2014). Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncology Report, 32(6), 2605–2611. Li, X., Liu, Y., Wu, B., Dong, Z., Wang, Y., Lu, J., et al. (2014). Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncology Report, 32(6), 2605–2611.
85.
Zurück zum Zitat Hall, C. L., Kang, S., MacDougald, O. A., & Keller, E. T. (2006). Role of Wnts in prostate cancer bone metastases. Journal of Cellular Biochemestry, 97(4), 661–672.CrossRef Hall, C. L., Kang, S., MacDougald, O. A., & Keller, E. T. (2006). Role of Wnts in prostate cancer bone metastases. Journal of Cellular Biochemestry, 97(4), 661–672.CrossRef
86.
Zurück zum Zitat Iuliani, M., Pantano, F., Buttigliero, C., Fioramonti, M., Bertaglia, V., Vincenzi, B., et al. (2015). Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget, 6(14), 12520–12528.PubMedCentralPubMedCrossRef Iuliani, M., Pantano, F., Buttigliero, C., Fioramonti, M., Bertaglia, V., Vincenzi, B., et al. (2015). Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget, 6(14), 12520–12528.PubMedCentralPubMedCrossRef
88.
Zurück zum Zitat Santoni, M., Scarpelli, M., Mazzucchelli, R., Lopez-Beltran, A., Cheng, L., Epstein, J. I., et al. (2015). Current histopathologic and molecular characterizations of prostate cancer: towards individualized prognosis and therapies. European Urology. doi:10.1016/j.eururo.2015.05.041. Santoni, M., Scarpelli, M., Mazzucchelli, R., Lopez-Beltran, A., Cheng, L., Epstein, J. I., et al. (2015). Current histopathologic and molecular characterizations of prostate cancer: towards individualized prognosis and therapies. European Urology. doi:10.​1016/​j.​eururo.​2015.​05.​041.
Metadaten
Titel
The origin of prostate metastases: emerging insights
verfasst von
Matteo Santoni
Francesco Piva
Marina Scarpelli
Liang Cheng
Antonio Lopez-Beltran
Francesco Massari
Roberto Iacovelli
Rossana Berardi
Daniele Santini
Rodolfo Montironi
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 4/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9597-6

Weitere Artikel der Ausgabe 4/2015

Cancer and Metastasis Reviews 4/2015 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.